Targets FDA Submission
Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that its collaboration with Tanaka Kapec Design Group (TKDG) has led to the completion of the design development phase for its Save A Life choking rescue device. Odyssey's patented Save A Life choking rescue device is now entering the prototyping phase of its development plan.
The prototypes will be utilized by TKDG, Odyssey and expert medical practitioners for testing and improving functional outcomes for rapid treatment of choking emergencies. During the design development phase, TKDG/Odyssey optimized the device's aperture diameter and aperture shape resulting in improved ergonomics, increased power with high efficiency and ease of use.
Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "We are excited to enter our next development phase for our choking rescue device, Save A Life. Our design and development partner Tanaka Kapec Design Group has been instrumental with their excellent and timely work. We are moving towards our goal of a regulatory submission to the FDA."
About Tanaka Kapec Design Group
Simple solutions to strategic product development challenges. Breakthrough innovation in industrial design. A reputation for delivering industrial product design excellence. With over 40 years of extensive experience, we understand the medical industry. Our designers have logged hundreds of hours studying clinical practice and procedures in the OR, surgical suites, central supply, labs, diagnostics, and treatment centers. We understand the realities surrounding medical product development. We understand the impact of good ergonomic design imparted in surgical instruments, diagnostic equipment, drug delivery systems, and packaging. TKDG aligns a human-centered, three-dimensional development process that delivers outstanding outcomes, affecting how medical products engage the physician and convey intelligent design.
For additional information, please visit: http://www.wedesigntosimplify.com
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions.
Media and Investors Contacts:
619-832-2900
This email address is being protected from spambots. You need JavaScript enabled to view it.
ClearThink
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.03 |
Daily Change: | -0.0005 -1.82 |
Daily Volume: | 1,150 |
Market Cap: | US$2.610M |
November 16, 2023 February 07, 2023 November 23, 2022 November 01, 2022 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB